Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00426556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Study identification
- NCT ID
- NCT00426556
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Interventions
- Everolimus Drug
- Trastuzumab Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Feb 28, 2014
- Completion
- Feb 28, 2014
- Last update posted
- Dec 27, 2015
2007 – 2014
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Wilshire Oncology Medical Group La Verne | *see Various Departments* | California | — | — |
| Compassionate Cancer Care Medical Group Dept.ofCCCMG | Fountain Valley | California | 92708 | — |
| Loma Linda University Dept.ofLomaLindaCancerCent(3) | Loma Linda | California | 92354 | — |
| University of California at Los Angeles Dept.of UCLA Dept.ofMed. | Los Angeles | California | 90095 | — |
| Florida Cancer Research Institute | Davie | Florida | 33328 | — |
| Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) | Atlanta | Georgia | 30322 | — |
| North Shore University Health System | Evanston | Illinois | 60201 | — |
| Peninsula Regional Medical Center Deptof Oncology and Hematology | Salisbury | Maryland | 21801 | — |
| Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CRAD001J2101 | St Louis | Missouri | 63110 | — |
| Cancer Centers of the Carolinas CC of C -Eastside | Greenville | South Carolina | 29605 | — |
| Sammons Cancer Center - Texas Oncology | Dallas | Texas | 78246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00426556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 27, 2015 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00426556 live on ClinicalTrials.gov.